pharmaceuticalcommerce5d
ImmunityBio to Supply Recombinant BCG to Alleviate Tice BCG Shortage
FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.
GlobalData on MSN6d
FDA authorises ImmunityBio’s BCG alternative to treat bladder cancer
ImmunityBio has gained US Food and Drug Administration (FDA) authorisation for an expanded access programme to supply an ...
Cancer Therapy Advisor5d
FDA Allows Use of Recombinant BCG Through Expanded Access Program
The FDA has authorized an expanded access program that will allow for the use of a recombinant bacillus Calmette-Guerin product.
Renal & Urology News2d
FDA Allows Use of Recombinant BCG Through Expanded Access Program
Providers who are unable to source TICE BCG will now be able to access rBCG through the expanded access program. Developed by the Serum Institute of India, the rBCG product, which has been ...
Hosted on MSN6d
ImmunityBio Surges On FDA Green Light For Expanded Bladder Cancer Vaccine Access — Retail Buzz Intensifies
Shares of ImmunityBio Inc. surged 16.4% on Wednesday, marking their best session in over a month, and extended gains in after ...
Investing6d
FDA approves expanded access for ImmunityBio's bladder cancer drug
to supply a new Bacillus Calmette-Guérin (BCG) source for bladder cancer treatment in the U.S. This development comes as a response to the shortage of TICE® BCG, which has affected patient treatment ...